Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Pharmacological Properties of 5-Hydroxytryptamine4Receptor Antagonists on Constitutively Active Wild-Type and Mutated Receptors

Sylvie Claeysen, Michèle Sebben, Carine Bécamel, Richard M. Eglen, Robin D. Clark, Joël Bockaert and Aline Dumuis
Molecular Pharmacology July 2000, 58 (1) 136-144; DOI: https://doi.org/10.1124/mol.58.1.136
Sylvie Claeysen
1 2
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michèle Sebben
1 2
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carine Bécamel
1 2
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard M. Eglen
1 2
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robin D. Clark
1 2
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joël Bockaert
1 2
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aline Dumuis
1 2
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

We studied the pharmacological properties of twenty-four 5-hydroxytryptamine (5-HT)4 receptor ligands known to act as antagonists on 5-HT4 receptors positively coupled to adenylyl cyclase endogenously expressed in mouse colliculi neurons. In COS-7 cells expressing human or mouse 5-HT4(a) receptors (100–8000 fmol/mg of protein), we found neutral antagonists, partial agonists, and inverse agonists. The majority of neutral antagonists belong to the benzodioxanyl ketone class, whereas partial agonists belong to different chemical classes. We found only two inverse agonists, GR 125487 and SB 207266, which are both indoles. Analysis of pharmacological characteristics of the constitutively active wild-type and constitutively active mutated receptors revealed that 1) the ratio between the efficiencies of the full agonist 5-HT and the partial agonist RS 23597 was invariable when the receptor density increased, but was dependent on receptor structure; 2) similarly, the efficacy of the inverse agonist SB 207266 was not dependent on receptor density but was dependent on receptor structure; 3) when the receptor concentration increased, the EC50 values of the full agonist 5-HT were not modified and the increase in basal constitutive activity, as well as its stimulation by 5-HT, followed a parallel evolution; and 4) the stimulation of basal constitutive activity by 5-HT was not modified by the overexpression of Gαs. All these results indicate that in COS-7 cells, the coupling of the 5-HT4 receptor to adenylyl cyclase was linear with no indication of spare receptors even at high receptor density (8 pmol/mg). These results are also in accordance with a precoupling between the activated receptor (f R*) and adenylyl cyclase. Such observations allowed us to use the two-state model to calculate the constant J, i.e., the equilibrium allosteric constant denoting the ratio of the receptor in the inactive versus active state (J = [R]/[R*]). We found that J was a receptor structural characteristic, independent of receptor density.

Footnotes

    • Received September 13, 1999.
    • Accepted March 16, 2000.
  • Send reprint requests to: Joël Bockaert, Centre National de la Recherche Scientifique Unité Propre de Recherche 9023, Centre National de la Recherche Scientifique-Institut National de la Santé et de la Recherche Médicale de Pharmacologie-Endocrinologie, 141 rue de la Cardonille, 34094 Montpellier cedex 5, France. E-mail: bockaert{at}ccipe.montp.inserm.fr

  • This study was supported by grants from the Foundation pour la Recherche Médicale and Roche Bioscience.

  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology: 58 (1)
Molecular Pharmacology
Vol. 58, Issue 1
1 Jul 2000
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Pharmacological Properties of 5-Hydroxytryptamine4Receptor Antagonists on Constitutively Active Wild-Type and Mutated Receptors
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Pharmacological Properties of 5-Hydroxytryptamine4Receptor Antagonists on Constitutively Active Wild-Type and Mutated Receptors

Sylvie Claeysen, Michèle Sebben, Carine Bécamel, Richard M. Eglen, Robin D. Clark, Joël Bockaert and Aline Dumuis
Molecular Pharmacology July 1, 2000, 58 (1) 136-144; DOI: https://doi.org/10.1124/mol.58.1.136

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Pharmacological Properties of 5-Hydroxytryptamine4Receptor Antagonists on Constitutively Active Wild-Type and Mutated Receptors

Sylvie Claeysen, Michèle Sebben, Carine Bécamel, Richard M. Eglen, Robin D. Clark, Joël Bockaert and Aline Dumuis
Molecular Pharmacology July 1, 2000, 58 (1) 136-144; DOI: https://doi.org/10.1124/mol.58.1.136
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Cysteine151 in Keap1 Drives CDDO-Me Pharmacodynamic Action
  • Allosteric Modulation of Metabotropic Glutamate Receptor 1
  • Mechanism of Selective Action of Paraherquamide A
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics